The study evaluates the efficacy of a new quadrivalent mRNA influenza vaccine, finding it to be highly immunogenic and protective in a mouse model. Compared to traditional vaccines, the mRNA-based option offers advantages like reduced production time and elimination of the risk of growth-promoting mutations.